Sign In
Buy LLY
$1,169.86
+53.75 (+4.82%)
At Close: Aug 05, 2026
Why Eli Lilly (LLY) is a Top Growth Stock for the Long-Term
10:46am, Thursday, 16'th Apr 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
LLY Stock Down as FDA Asks for More Safety Data on Oral Obesity Pill
10:36am, Thursday, 16'th Apr 2026
LLY stock slips after FDA seeks added safety data on its new oral obesity pill Foundayo, raising questions despite blockbuster sales hopes.
Eli Lilly Partner MeiraGTx Regains Rights For Genetic Eye Disease Drug From Johnson & Johnson
10:16am, Thursday, 16'th Apr 2026
XLRP is a severe, progressive genetic eye disease causing early-onset night blindness and peripheral vision loss, leading to legal blindness by age 40–45.
How Will Mounjaro and Zepbound Sales Aid LLY's Upcoming Q1 Results?
10:05am, Thursday, 16'th Apr 2026
Eli Lilly's Q1 revenues are expected to reflect strong Mounjaro and Zepbound demand, as supply gains and global uptake offset pricing pressure.
Lilly confirms date and conference call for first-quarter 2026 financial results announcement
10:00am, Thursday, 16'th Apr 2026
INDIANAPOLIS, April 16, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2026 financial results on April 30, 2026. Lilly will also conduct a conference call that
Is This $6.3 Billion Deal a Game Changer for Eli Lilly?
09:30am, Thursday, 16'th Apr 2026
It won't come cheap, as Eli Lilly is paying $6.3 billion in up-front payments in the deal. The pharmaceutical giant is also on the hook for up to $1.5 billion in milestone payments.
Eli Lilly Reveals Results of Late-Stage Study for Type 2 Diabetes Treatment
07:47am, Thursday, 16'th Apr 2026
Eli Lilly's late-stage study of the efficacy and safety of a treatment for type 2 diabetes has produced positive results.
In ACHIEVE-4, Foundayo met the primary objective of non-inferiority vs. insulin glargine with a 16% lower risk of MACE-4 events and a 23% lower risk of MACE-3 events In a pre-planned analysis, the ris
Prediction: This 1 Thing Could Cement Eli Lilly's Leadership in the Billion-Dollar Weight Loss Drug Market
04:08am, Thursday, 16'th Apr 2026
Eli Lilly has taken the lead over Novo Nordisk in the U.S. weight loss drug market. Both companies sell blockbusters and have recently released new products.
Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know
06:46pm, Wednesday, 15'th Apr 2026
Eli Lilly (LLY) concluded the recent trading session at $905.03, signifying a -1.89% move from its prior day's close.
The $1 Trillion Race: Why Eli Lilly Is Leaving Novo Nordisk in the Dust
01:26pm, Wednesday, 15'th Apr 2026
Eli Lilly has a stronger weight-loss portfolio than Novo Nordisk. Eli Lilly also has a deep pipeline beyond its core therapeutic area.
Worried About a Stock Market Crash? These 3 Stocks Beat the S&P 500 by Wide Margins When It Nosedived in 2022, and They Could Do It Again
11:30am, Wednesday, 15'th Apr 2026
Exxon Mobil, Eli Lilly, and Berkshire Hathaway all have strong fundamentals and have done well in the past, even when the stock market has struggled. These stocks all outperformed the market in 2022 d
Carnegie Investment Counsel Sells 894 Shares of Eli Lilly and Company $LLY
04:34am, Wednesday, 15'th Apr 2026
Carnegie Investment Counsel reduced its position in Eli Lilly and Company (NYSE: LLY) by 7.2% in the undefined quarter, according to the company in its most recent disclosure with the Securities and E
LLY Stock To $2,000?
10:36am, Tuesday, 14'th Apr 2026
Can Eli Lilly (NYSE: LLY) stock surge 2x to $2,000 in the coming years? We believe that this is indeed a genuine possibility.
Linden Lake Labs Applauds Acquisition of Portfolio Company CrossBridge Bio by Eli Lilly and Company
09:00am, Tuesday, 14'th Apr 2026
ROCKVILLE, Md.--(BUSINESS WIRE)--Linden Lake Labs (“L3”), an early-stage life sciences platform committed to advancing innovative therapies, today announced that its portfolio company, CrossBridge
